Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NEXGEL, Inc. (NASDAQ: NXGL) generates news across healthcare, consumer products, and capital markets through developments tied to its ultra-gentle, high-water-content hydrogel technology. The company regularly issues press releases on quarterly financial results, highlighting performance in its contract manufacturing segment and its portfolio of consumer-branded products in health, beauty, and OTC categories.
Investors following NXGL news will see updates on earnings announcements, including revenue trends, gross margin, operating expenses, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Management commentary often discusses demand for branded products, new contract manufacturing agreements, and the impact of partnerships with consumer healthcare companies.
NEXGEL’s news flow also covers strategic and corporate actions. Recent items include the spin-off of select drug delivery application assets into NexGelRx, with NEXGEL retaining a royalty interest, an equity stake, and exclusive hydrogel manufacturing rights. Additional releases have described expanded partnerships, such as the agreement with STADA Arzneimittel AG involving non-dilutive capital to support product launches and marketing efforts, as well as financing transactions like registered direct offerings and concurrent private placements.
Governance and leadership developments are another recurring news theme. NEXGEL has announced board appointments, conference presentations at investor events, and changes in senior finance roles through its press releases and associated SEC filings. Readers of this NXGL news page can review these updates in one place, including information on special meetings of stockholders, strategic advisors to NexGelRx, and other events that shape the company’s direction.
By monitoring the NXGL news feed, market participants can track how NEXGEL’s hydrogel-focused business, partnerships, financings, and governance decisions evolve over time, using official company communications as a primary source.
NEXGEL (NASDAQ: NXGL) appointed Brian J. Kieser, CPA and Kevin Harris, CFA from strategic partner Sequence LifeScience to its Board of Directors on May 6, 2026.
Sequence LifeScience led financing to close the acquisition of Celularity's degenerative disease segment with a $5.5 million strategic investment; management highlights partnership, industry experience, product innovation, and distribution support.
NEXGEL (NASDAQ:NXGL) named Ian Blackman, CPA, as Chief Financial Officer effective April 27, 2026. Mr. Blackman will support closing and integration of a definitive agreement to license and acquire commercial-stage regenerative biomaterial products from Celularity and scale NEXGEL’s consumer and healthcare businesses.
He brings over 30 years of finance and M&A experience, prior CFO roles in luxury consumer companies, and a record of revenue and EBITDA expansion in prior positions.
NEXGEL (NASDAQ: NXGL) closed the license and acquisition of Celularity's commercial-stage regenerative biomaterials portfolio and launched BioNX Surgical. The deal is led by a $5.5 million strategic investment from Sequence LifeScience™ and financed via a convertible note with a $0.60 conversion price and 50% warrant coverage. The transaction is expected to approximately triple pro-forma annual revenue to about $35 million and be immediately accretive to profitability, adding 6 established products with existing reimbursement and accelerating commercialization.
NEXGEL (NASDAQ:NXGL) moved its shareholder update conference call to April 21, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the company webcast under Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 23, 2026 at 4:30 P.M. ET to provide an update on the proposed transaction with Celularity.
The company said it will not finance the transaction under its previously announced Securities Purchase Agreement and is negotiating a new financing with a different investor group; additional details are expected on April 23.
Call details include U.S. toll-free 1-800-267-6316, international 1-203-518-9783, and a webcast via Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 15, 2026 at 4:30 P.M. ET to provide an update on the proposed Celularity transaction. The company said there is no assurance the transaction will close and it will not use the previously announced Securities Purchase Agreement financing.
The company is negotiating a new financing structure with a different group of investors and expects to provide additional transaction details on the April 15 call. Call and webcast access information has been provided for shareholders.
NEXGEL (NASDAQ:NXGL) rescheduled its fourth quarter and full-year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to allow more time to provide shareholders detail on its previously announced proposed transaction with Celularity.
The company filed its Form 10-K for year ended December 31, 2025 with the SEC on March 31, 2026. Call dial-in numbers and a webcast will be available for investors.
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
NEXGEL (NASDAQ: NXGL) announced terms to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU).
Key terms: $15 million upfront cash plus up to $20 million in milestone payments tied to net sales. The company says the deal should roughly triple revenue to ~ $35 million and make NEXGEL immediately profitable upon closing. The portfolio targets tendon repair, skin grafts, and bone growth, includes decade-long clinical use and reimbursement pathways, adds commercial/scientific staff, and remains subject to customary closing and financing.
NEXGEL (NASDAQ: NXGL) signed a definitive agreement to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity, a deal expected to approximately triple NEXGEL’s annual revenue to about $35 million and make the company immediately profitable upon closing.
The portfolio includes established products with existing insurance reimbursement, plans for three 510(k) filings in 2026–2028, and an experienced commercial team expected to join. The company anticipates approximately $14.9 million of additional financing in Q1 or early Q2 2026; closing remains subject to customary closing processes and financing.